Recent Advances in Hodgkin's Lymphoma Treatment in Adults

Efficacy

Increased-dose BEACOPP Resulted in Better Tumor Control and Overall Survival Than COPP-ABVD*1

*COPP-ABVD denotes cyclophosphamide, vincristine. procarbazine, prednisone, doxorubicin, blemycin, vintiastine, and dacarbazine. BEACOPP denotes bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and brednisone. In the increased-dose BEACOPP arm, cyclophosphamide, etoposide, and dexoruticin were increased by 192%, 200%, and 140% of standard dosage, respectively.

A Rigorous, Randomized, and Controlled Trial1

  • 1195 patients 15-65 years of age (median age in increase-dose BEACOPP group was 31.5)
  • The overall 5-year survival rate was significantly higher with increased-dose BEACOPP than standard BEACOPP (91% vs 88% P=0.06) and COPP-ABVD (91% vs 83% P=0.002)
  • Progression occured in significantly fewer patients with increased-dose BEACOPP than standard BEACOPP (2% vs 8% P<0.001) and COPP-ABVD (2% vs 10% P<0.001)
  • The rate of freedom from treatment failure was significantly higher at 5 years with increased-dose BEACOPP than standard BEACOPP (87% vs 76% P<0.0001) and COPP-ABVD (87% vs 69% P<0.001)
  • Enrollment in COPP-ABVD arm was discontinued in 1996 due to inferior results
  • The occurrence to acute leukemia after increased-dose BEACOPP must be weighted against the lower rate of early progression and higher rates to failure-free survival and overall survival rates at 5 years
  • The incidence of acute hematologic effects was greatly increased in the increased-dose BEACOPP group

Back To Top

Increased-dose BEACOPP Resulted in Better Rates of Remission, Early Progression, and Freedom From Treatment Failure

Back To Top

Long-term Survival Benefit With Increased-dose BEACOPP Versus COPP-ABVD

Reference:

  1. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-2395.

Back To Top

Important Safety Information

WARNING
It is recommended that MATULANE be given only by or under the supervision of a physician experienced in the use of potent antineoplastic drugs. Adequate clinical and laboratory facilities should be available to patients for proper monitoring of treatment.

Matulane is contraindicated in patients with known hypersensitivity to the drug or inadequate marrow reserve as demonstrated by bone marrow aspiration. Due consideration of this possible state should be given to each patient who has leukopenia, thrombocytopenia, or anemia.

Matulane in combination therapy is a potent chemotherapeutic agent. Before prescribing Matulane, the sections in the Prescribing Information concerning usage in pregnancy, occurrence of secondary cancers, monitoring required in liver and kidney disease, hematologic effects, CNS effects, and potentiation associated with alcohol and MAO inhibitors should be carefully evaluated.

Please see full Prescribing Information for Matulane indications and usage, contraindications, and warnings including boxed WARNINGS, precautions, and adverse reactions.